Clinical Trial Update: A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Alone or in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating AK104 alone or in combination with lenvatinib for advanced Hepatocellular Carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• AK104 (PD-1/CTLA-4 bispecific antibody)
• Lenvatinib (lenvatinib)

Snippet

Sponsor: Akeso | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: COMPLETED